ZLSCF (ZYUS Life Sciences) Growth Rank: 0 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.60
GF Value $0.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Growth Rank?

ZYUS Life Sciences has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ZYUS Life Sciences Growth Rank Related Terms

ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued. The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55. GuruFocus considers ZYUS Life Sciences to be Fairly Valued.

Key valuation signals for ZLSCF:

  • Growth Rank: 0
  • GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.55
GF Value